Home › Therapeutic areas › Oncology › Pancreatic Cancer
Pancreatic Cancer (27 companies)
Companies with an active program in Pancreatic Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $69.0M | 9 |
| ACTU | Actuate Therapeutics | Oncology | 1 | Phase 2 | $7.9M | 4 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $360M | 10 |
| DRTS | Alpha Tau Medical | Oncology | 1 | Phase 2 | $1.27B | 6 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 1 | Phase 3 | $2.63B | 8 |
| BCYC | Bicycle Therapeutics | Oncology | 1 | Phase 2 | $253M | 4 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 2 | Phase 1 | $164M | 6 |
| CLRB | Cellectar Biosciences | Oncology | 1 | Phase 2 | $11.8M | 6 |
| CTMX | CytomX Therapeutics | Oncology | 1 | Phase 1 | $477M | 7 |
| EIKN | Eikon Therapeutics | Oncology | 2 | Phase 2 | $320M | 13 |
| ELTX | Elicio Therapeutics | Oncology | 2 | Phase 2 | $42.7M | 6 |
| ERAS | Erasca | Oncology | 1 | Phase 1 | $5.04B | 5 |
| IDYA | IDEAYA Biosciences | Oncology | 1 | NDA Submitted | $3.02B | 14 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | $238M | 5 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 2 | Approved | $9.15B | 16 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $647M | 12 |
| LEGN | Legend Biotech | Oncology Rare | 1 | Approved | $4.55B | 17 |
| MRKR | Marker Therapeutics | Oncology | 1 | Phase 1 | $14.8M | 4 |
| MBRX | Moleculin Biotech | Oncology | 1 | Phase 2 | — | 8 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | $106M | 7 |
| ONCY | Oncolytics Biotech | Oncology | 1 | Phase 2 | $56.1M | 3 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $67.4M | 7 |
| RVMD | Revolution Medicines | Oncology | 2 | Approved | $41.6B | 11 |
| SLS | SELLAS Life Sciences Group | Oncology | 1 | Phase 3 | $1.70B | 9 |
| TNGX | Tango Therapeutics | Oncology | 1 | Phase 1 | $3.63B | 4 |
| VSTM | Verastem | Oncology | 2 | Approved | $1.06B | 5 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
No companies match.